Abstract

Cancer is definitely one of the leading causes of mortality worldwide. Failure in the efficacy of the standard treatments (chemo-, radiotherapy and surgery), and the severe side effects, resistance of tumor cells to chemotherapeutics have necessitated alternative therapeutic strategies. Magnetic nanoparticles (MNPs) have been assessed as potential cancer therapy materials. Their intrinsic magnetic properties provide a cancer detection, monitoring, and therapy platform based on multimodal theranostics. MNPs can be functionalized by binding them to a wide variety of substances, including chemotherapeutic drugs, radionuclides, nucleic acids, and antibodies. They can be used for drug delivery, magnetic or photothermal induced local hyperthermia and photodynamic therapy aimed at killing cancer cells at the tumor site. MNPs may also be useful to challenge drug resistance. The combination of different options of these treatment modalities offers a synergistic effect and significantly reduces the side effects. The functionalized MNPs may be used to remove the unwanted cells from blood, including leukemia cells and circulating tumor cells that key factors in the metastatic process. Despite numerous successful studies, there are still some unpredictable obstacles relevant to the use of MNPs in cancer therapy. This review mainly focuses on the application of MNPs in cancer treatment, covering future perspectives and challenges aspects.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.